Twenty-carbon signaling lipid molecules derived primarily from arachidonic acid (omega-6) or EPA/DHA (omega-3) via enzymatic oxidation. These autocrine and paracrine mediators regulate inflammation initiation, amplification, and resolution, controlling vascular tone, pain sensitization, immune cell recruitment, fever generation, and tissue repair. The eicosanoid family includes prostaglandins, leukotrienes, thromboxanes, lipoxins, resolvins, protectins, and maresins.
Imagine a neighborhood fire department that operates in two completely different modes depending on which fuel source it's using. When burning coal (omega-6 arachidonic acid), it produces thick black smoke signals (PGE2, LTB4) that rapidly recruit firefighters, cause sirens and alarms (pain, fever), close roads (vasoconstriction), and create maximum alert status. But when the same department switches to burning clean natural gas (omega-3 EPA/DHA), the same engine produces gentler white smoke (resolvins, lipoxins) that signals "all clear," tells firefighters to go home, reopens roads, and transitions to cleanup mode. The fire chief (PLA2) decides when to release fuel from storage tanks (cell membranes), and three different furnace types (COX, 5-LOX, 12/15-LOX) each produce different smoke patterns. Aspirin and NSAIDs are like shutting down the entire fire stationβyou stop both the alarm signals AND the all-clear signals, which is why inflammation sometimes can't fully resolve when you block these pathways chronically.
Eicosanoid synthesis begins when cellular stress, injury, immune activation, hypoxia, or oxidative stress (via PDGF, EGF, thrombin, complement factors, or reactive oxygen species) activates PLA2 (phospholipase A2). PLA2 cleaves arachidonic acid (20:4 n-6) or EPA (20:5 n-3) from the sn-2 position of membrane phospholipids, releasing free fatty acid substrate into the cytoplasm.
Three major enzymatic pathways then compete for this substrate:
1. Cyclooxygenase (COX) Pathway:
- COX-1 (constitutive) or COX-2 (inducible) β converts arachidonic acid to PGG2 β PGH2 (unstable intermediate)
- Tissue-specific synthases convert PGH2 to:
- PGE2 (via PGE synthase) β vasodilation, fever (acts on EP receptors in hypothalamus), pain sensitization, immune cell activation
- PGI2 (prostacyclin) β vasodilation, anti-platelet
- TXA2 (via thromboxane synthase) β vasoconstriction, platelet aggregation
- PGD2 β sleep promotion, mast cell mediator
2. Lipoxygenase (LOX) Pathways:
- 5-LOX (+ FLAP cofactor) β 5-HPETE β LTB4 (neutrophil chemoattractant) or cysteinyl leukotrienes (LTC4/D4/E4, potent bronchoconstrictors)
- 12-LOX β 12-HPETE β lipoxin precursors
- 15-LOX β 15-HPETE β lipoxins (LXA4, LXB4) when combined with 5-LOX
3. Resolution Pathways:
When EPA/DHA serve as substrate:
These specialized pro-resolving mediators (SPMs) bind to GPCRs (GPR32, ALX-FPR2, GPR18) to:
- Stop neutrophil recruitment
- Enhance macrophage efferocytosis (clearance of apoptotic cells)
- Reduce NF-ΞΊB activation
- Counter-regulate pro-inflammatory eicosanoid signaling
- Promote tissue repair and regeneration
graph TD
A[Cellular Stress/Injury] --> B[PLA2 Activation]
B --> C["Arachidonic Acid 20:4 n-6"]
B --> D["EPA 20:5 n-3 / DHA 22:6 n-3"]
C --> E[COX-1/COX-2]
C --> F[5-LOX]
C --> G[12/15-LOX]
E --> H[PGH2]
H --> I["PGE2: Fever, Pain, Vasodilation"]
H --> J["TXA2: Platelet Aggregation"]
F --> K["LTB4: Neutrophil Recruitment"]
F --> L["Cysteinyl LTs: Bronchoconstriction"]
G --> M["Lipoxins: Pro-Resolution"]
D --> N[COX-2 Acetylated]
D --> O[15-LOX]
D --> P[12-LOX Macrophage]
N --> Q[Resolvins E-series, D-series]
O --> R[Protectins PD1/NPD1]
P --> S[Maresins MaR1/2]
Q --> T["Resolution: Stop Inflammation"]
R --> T
S --> T
M --> T
style I fill:#ffcccc
style K fill:#ffcccc
style L fill:#ffcccc
style T fill:#ccffcc
The eicosanoid system represents a fundamental therapeutic leverage point in cPNI because it directly translates membrane fatty acid composition into inflammatory phenotype. This is metamodel-level intervention: changing substrate availability (via omega-3 supplementation and reduced omega-6 intake) reprograms the entire inflammatory resolution capacity.
Omega-6 to Omega-3 Ratio:
Modern Western diets exhibit 15:1 to 20:1 omega-6:omega-3 ratios (evolutionary baseline ~1-4:1), creating an arachidonic acid-dominated membrane pool that biases toward pro-inflammatory eicosanoid production. Clinical target: achieve β€4:1 ratio via dietary intervention.
Hypothalamic Neuroinflammation:
The additional 1g/day omega-3 supplementation in cPNI protocols (providing ~600-700mg combined EPA+DHA) specifically targets hypothalamic inflammation by shifting local eicosanoid synthesis from PGE2-mediated inflammatory signaling to resolvin/protectin-mediated resolution. This addresses the root of metabolic syndrome, insulin resistance, and neuroendocrine dysregulation.
Resolution Deficiency Syndrome:
Many chronic inflammatory conditions (rheumatoid arthritis, inflammatory bowel disease, atherosclerosis, Alzheimer's Disease) show not just excessive pro-inflammatory eicosanoid production but deficient SPM synthesis. Measuring plasma resolvin/protectin/maresin levels (emerging biomarker panel) may identify resolution failures requiring targeted omega-3 intervention.
NSAID Paradox:
NSAIDs block both arms of the COX pathwayβstopping inflammatory prostaglandin synthesis but also preventing aspirin-triggered resolvin formation and lipoxin synthesis. Chronic NSAID use can create iatrogenic resolution failure, explaining why some pain conditions worsen or fail to heal with long-term NSAID therapy. Clinical strategy: use NSAIDs acutely only, then transition to resolution support.
Wound Healing:
The "eicosanoid class switch" is essential for proper tissue repair. Initial PGE2/LTB4 production recruits immune cells and creates inflammatory barrier (days 1-3), followed by lipoxin/resolvin production initiating cleanup and collagen deposition (days 4-14). Failure to switch (due to insufficient omega-3 substrate or persistent infection) leads to chronic wounds or excessive fibrosis.
Clinical Thresholds:
- PGE2 >150 pg/mL in synovial fluid indicates active inflammatory arthritis
- LTB4 >200 pg/mL associated with acute inflammatory episodes
- Omega-3 index (RBC EPA+DHA) target: >8% for optimal SPM synthesis capacity
- Resolvin D1 <50 pg/mL suggests resolution deficiency in chronic inflammation
Intervention Strategy:
- Reduce omega-6 intake (eliminate seed oils, reduce grain-fed animal products)
- Increase omega-3 EPA+DHA 2-4g/day (higher doses for active inflammation)
- Support COX-2 pathway with moderate aspirin doses (enables aspirin-triggered resolvins)
- Address underlying PLA2 triggers (insulin resistance, oxidative stress, persistent infection)
- Measure omega-6:omega-3 ratio and omega-3 index to personalize dosing
- 20-carbon fatty acid derivatives named from Greek "eicosa" (twenty)
- Produced locally at inflammation sites within seconds to minutes (autocrine/paracrine only)
- Half-life typically 30 seconds to 5 minutes (rapid synthesis and degradation)
- PGE2 is the primary fever mediator, acting on EP3 receptors in hypothalamus to reset thermostat upward
- LTB4 is 100-fold more potent as neutrophil chemoattractant than classical chemokines
- Lipoxins were the first endogenous "stop signals" discovered (1984), named for "lipoxygenase interaction products"
- Aspirin uniquely acetylates COX-2 at Ser-530, converting it from pro-inflammatory to pro-resolving enzyme
- Omega-3 derived eicosanoids are generally 2-3 orders of magnitude less inflammatory than omega-6 versions (e.g., LTB5 vs LTB4)
- Neutrophils predominantly express 5-LOX, while endothelial cells express COX-2βcell-type determines eicosanoid profile
- PLA2 activation is the rate-limiting step, triggered by increased intracellular CaΒ²βΊ, MAPK phosphorylation, or direct oxidative modification
- Resolvins actively stimulate macrophage efferocytosis (clearing apoptotic neutrophils) at nanomolar concentrations
- Protectins cross the blood-brain barrier and protect against neuroinflammation in CNS injury models
- arachidonic acid β primary omega-6 precursor stored in membrane phospholipids, released by PLA2
- EPA β omega-3 precursor for E-series resolvins and less inflammatory 5-series leukotrienes
- DHA β omega-3 precursor for D-series resolvins, protectins, and maresins; essential for CNS resolution
- prostaglandins β COX pathway products including PGE2 (fever, pain), PGI2 (vasodilation), and PGD2 (sleep)
- leukotrienes β 5-LOX pathway products, potent bronchoconstrictors and neutrophil chemoattractants
- lipoxins β first endogenous pro-resolving eicosanoids, require both 5-LOX and 12/15-LOX interaction
- resolvins β specialized pro-resolving mediators from EPA/DHA, actively terminate inflammation
- protectins β DHA-derived SPMs, particularly important in neural tissue and retina
- maresins β macrophage-produced resolving mediators from DHA, enhance tissue regeneration
- COX-2 β inducible enzyme producing both pro-inflammatory and (when acetylated) pro-resolving eicosanoids
- 5-LOX β enzyme producing leukotrienes from arachidonic acid, requires FLAP cofactor
- PLA2 β rate-limiting enzyme releasing fatty acids from membranes, activated by stress signals
- inflammation β eicosanoids are primary mediators of all cardinal signs (rubor, calor, dolor, tumor)
- pain β PGE2 and PGI2 sensitize nociceptors via EP and IP receptor activation on A-delta fibres and C-fibres
- fever β PGE2 acts on EP3 receptors in preoptic hypothalamus to elevate temperature set point
- omega-3 supplementation β increases membrane EPA/DHA, shifts eicosanoid profile toward resolution
- omega-6 to omega-3 ratio β determines substrate competition for COX and LOX enzymes, optimal <4:1
- NSAIDs β block COX-1/COX-2, preventing both inflammatory and resolving eicosanoid synthesis
- resolution of inflammation β specialized eicosanoids (SPMs) actively drive this process rather than passive decay
- hypothalamic neuroinflammation β omega-3 supplementation reduces via increased resolvin/protectin production in hypothalamus
- neutrophils β primary source of 5-LOX and LTB4, recruited by eicosanoid gradients
- macrophages β produce maresins via 12-LOX, switch from M1 to M2 phenotype under SPM influence
- insulin resistance β PGE2 in adipose tissue impairs insulin signaling, resolved by lipoxin/resolvin action
- atherosclerosis β imbalanced eicosanoid production (excess LTB4, deficient resolvins) drives plaque inflammation
- asthma β cysteinyl leukotrienes cause bronchoconstriction, resolvin deficiency prevents airway resolution
- wound healing β requires coordinated eicosanoid class switch from pro-inflammatory to pro-resolving mediators
- aspirin β low-dose acetylates COX-2, creating aspirin-triggered resolvins and lipoxins
- collagen synthesis β regulated by eicosanoid balance, excess PGE2 can promote fibrosis
- blood-brain barrier β protectins and certain resolvins cross BBB to resolve neuroinflammation
- endothelial dysfunction β excess TXA2 and deficient PGI2 promote vasoconstriction and platelet activation
- Module 2 β Neuroendocrinology (hypothalamic inflammation, omega-3 intervention)
- Module 3 β Immunology (inflammatory mediators, resolution pathways)
- Module 5 β Wound Healing (eicosanoid class switch, collagen synthesis regulation)
- Module 6 β Organs (tissue-specific eicosanoid profiles)
- Module 10 β Clinical Practice (omega-3 supplementation protocols, NSAID considerations)